Advertisement

2 Results

for author "Stefan E. Sonderegger"

Type a term to search within all articles in this journal: e.g., stem cell
Citation
Citation-specific search information
e.g., 2009
e.g., 20
e.g., 3
e.g., 29
e.g., 10.9999/123XYZ456
Authors, Keywords
Search for specific authors and/or words and phrases.
e.g., Smith, JS
e.g., Smith, JS
Type any phrase that appears in the article title
Type any phrase that appears within article title or abstract
Type any phrase that appears within article body, title or abstract
e.g., Smith, JS
Book publisher name
Limit Results
Limit search results by date
Date of Publication
e.g., 2017-01-18
e.g., 2017-01-18
Format Results
  • Oncogenic ZEB2 activation drives sensitivity towards KDM1A inhibition in T-cell acute lymphoblastic leukemia
    Steven Goossens, Sofie Peirs, Wouter Van Loocke, Jueqiong Wang, Mina Takawy, Filip Matthijssens, Stefan E. Sonderegger, Katharina Haigh, Thao Nguyen, Niels Vandamme, Magdaline Costa, Catherine Carmichael, Filip Van Nieuwerburgh, Dieter Deforce, Oded Kleifeld, David J. Curtis, Geert Berx, Pieter Van Vlierberghe, Jody J. Haigh
    Oncogenic ZEB2 activation drives sensitivity towards KDM1A inhibition in T-cell acute lymphoblastic leukemia ~~~
  • Selective Inhibitors of Arginine Methyl Transferase 5 (PRMT5) As a Novel Treatment for β-Thalassemia and Sickle Cell Disease.
    Ian Street, Brendon Monahan, Hendrik Falk, Elizabeth Allan, Ylva Bergman, Paul Stupple, Ian Holmes, Alison Gregg, Susan Charman, Kurt Lackovic, Tom Peat, Scott Walker, Kym Lowes, Wilco Kersten, Jo Alcindor, Matthew Chung, Michael Parker, Richard Foitzik, Michelle Camerino, Marcia Nikac, Julian Grusovin, Pat Pilling, Stefan Sonderegger, Yuen Tan, Quan Zhao, David J. Curtis, Stephen M Jane
    Selective Inhibitors of Arginine Methyl Transferase 5 (PRMT5) As a Novel Treatment for -Thalassemia and Sickle Cell Disease. ~~~